Compare Ascendis Pharma A/S (ASND) vs 3M Company (MMM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs 3M Company — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while 3M Company trades at $157.3 (market cap $82.16B). The key difference: 3M Company is far larger — about 4.6× Ascendis Pharma A/S's market cap, and 3M Company pays a 1.98% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MMM | |
|---|---|---|
Market Cap | $17.74B | $82.16B |
Sector | Health | Industrials |
52-Week High | $277.18 | $174.61 |
52-Week Low | $163.32 | $141.10 |
Enterprise Value | $18.11B | $90.56B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
3M (MMM) trades at $157.52, up 1.4% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a 72.14% ROE and 13.03% net margin, though revenue has declined from 2022 peaks. Recent news highlights segment weakness in Consumer but strength in Safety & Industrial, alongside strategic partnerships like the Airbus A220 supply agreement.
Outlook is mixed: analyst consensus is cautious with a $148.75 price target below current levels, citing persistent consumer segment challenges. Investment appeal lies in dividend yield and cost optimization efforts, but risks include revenue stagnation and high debt levels. The stock faces headwinds from technical bearishness and modest growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
